阿立哌唑治疗女性阴性症状精神分裂症疗效研究

目的：研究阿立哌唑治疗女性阴性症状为主精神分裂症的疗效和安全性。方法：对符合CCMD-3精神分裂症诊断标准、阴性症状评定量表（SANS）≥50分、临床总体印象量表（CGI）≥4的60例女性分裂症患者。随机分为阿立哌唑治疗组和利培酮治疗组，疗程为8周。阿立哌唑组30例，口服阿立哌唑（20．52±5．28）mg／d；利培酮组（5．31±1．47）mg／d。用阴性症状量表（SANS）、临床总体印象量表（CGI）评定疗效，用药物副反应量表（TESS）评定不良反应。结果：经SANS、CGI评定，两组治疗后2周、4周、8周均与治疗前比较具有显著性差别（P〈0．01）。临床总体疗效在统计学上无显著性差别（P〉0．05），TESS量表评定，阿立哌唑组锥体外系反应少、无体重增加、月经紊乱及泌乳。利培酮组震颤、锥体外系反应、体重增加、月经紊乱、溢乳等反应发生率高。阿立哌唑副反应明显少于利培酮。结论：阿立哌唑治疗女性精神分裂症阴性症状临床疗效良好，且副作用小，安全性高。

Treatment Efficacy of Women with Negative Symptoms of Schizophrenia with Aripiprazole

Objective： To evaluate the efficacy and the safety of Aripiprazole and Risperidone for treatment of women with schizophrenia negative symptoms. Methods： Of 60 women with schizophrenia, who were eligible because CCMD-3 and SANS score≥50, and CGI score≥4, 30 were assigned to the aripiprazole group （20.52 ± 5.28mg/d for 8 weeks, oral） and 30 to the risperidone group（5.31 ± 1.47mg/d for 8 weeks, oral）. All participants were assessed by SANS , CGI and TESS before and after 2,4 and 8 weeks treatment. Results：There were signifieanfly difference on SANS and CGI between before and after treatment （P 〈 0.01 ）. The total clinical efficacy showed not statistically significant difference between two groups （P 〉 0.05 ）. Aripiprazole got a good response in all target symptoms of SANS and CGI and had fewer side effects than Risperidone. Conclusions：Aripiprazole has an effective treatment for women with schizophrenia negative symptoms and has fewer side effects.